Waters (WAT) Expected to Announce Earnings on Thursday

Waters (NYSE:WAT) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $4.50 per share and revenue of $928.1690 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, February 9, 2026 at 8:30 AM ET.

Waters (NYSE:WAT) last posted its quarterly earnings results on Tuesday, November 4th. The medical instruments supplier reported $3.40 EPS for the quarter, topping the consensus estimate of $3.21 by $0.19. The company had revenue of $799.89 million for the quarter, compared to the consensus estimate of $780.05 million. Waters had a net margin of 20.89% and a return on equity of 36.59%. The firm’s revenue was up 8.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.93 EPS. On average, analysts expect Waters to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Waters Price Performance

Waters stock opened at $384.62 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.08. The stock has a market cap of $22.90 billion, a price-to-earnings ratio of 35.35, a price-to-earnings-growth ratio of 3.17 and a beta of 1.18. The firm has a 50-day moving average of $388.89 and a two-hundred day moving average of $345.63. Waters has a 1 year low of $275.05 and a 1 year high of $417.10.

Hedge Funds Weigh In On Waters

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its holdings in shares of Waters by 112.9% in the 4th quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock valued at $471,000 after buying an additional 673 shares in the last quarter. Integrated Wealth Concepts LLC lifted its position in Waters by 2.9% during the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after acquiring an additional 30 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Waters by 3.6% during the first quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock valued at $73,733,000 after acquiring an additional 6,976 shares during the last quarter. Empowered Funds LLC boosted its stake in Waters by 16.6% in the first quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock valued at $415,000 after acquiring an additional 160 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new position in Waters in the second quarter worth $232,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on WAT. Weiss Ratings reiterated a “hold (c)” rating on shares of Waters in a report on Wednesday, January 21st. Guggenheim began coverage on Waters in a research report on Tuesday, January 6th. They set a “buy” rating and a $440.00 target price for the company. Wall Street Zen raised Waters from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. Morgan Stanley began coverage on Waters in a research note on Monday, December 1st. They set an “equal weight” rating and a $423.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on Waters from $300.00 to $325.00 and gave the company a “neutral” rating in a report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $398.61.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.